1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
Industrialization and Translation of Extracellular Vesicles for use in Regenerative Medicine (UT1/UT2) Clinical Trial Not Allowed is sponsored by National Institutes of Health (NIH). This funding opportunity invites eligible United States small business concerns to submit Small Business Technology Transfer (STTR) Phase I and Phase II (Fast track) grant applications.
Get a weekly digest of new grants like this
A free weekly digest of new foundation and federal funding opportunities as they're added to Granted. Unsubscribe anytime.
Or search similar grants →Extracted from the official opportunity page/RFP to help you evaluate fit faster.
NOT-TR-24-019: Notice of Change to Application Types Allowed in PAR-23-268 Industrialization and Translation of Extracellular Vesicles for use in Regenerative Medicine (UT1/UT2) Clinical Trial Not Allowed Notice of Change to Application Types Allowed in PAR-23-268 Industrialization and Translation of Extracellular Vesicles for use in Regenerative Medicine (UT1/UT2) Clinical Trial Not Allowed April 18, 2023 - Industrialization and Translation of Extracellular Vesicles for use in Regenerative Medicine (UT1/UT2 Clinical Trials Not Allowed).
See NOFO PAR-23-268 . National Center for Advancing Translational Sciences ( NCATS ) The purpose of this Notice is to change the application types allowed in PAR-23-268, Industrialization and Translation of Extracellular Vesicles for use in Regenerative Medicine, to include Renewal (Phase II) applications. Part 2.
Full Text of Announcement Section II. Award Information New (Phase I, Fast-Track) Resubmission (All Phases) Corrected to read (in bold italics): Resubmission (All Phases) New (Phase I, Fast-Track) All other aspects of the NOFO remain unchanged. Please direct all inquiries to: Office of Special Initiatives National Center for Advancing Translational Sciences (NCATS) Weekly TOC for this Announcement NIH...
Turning Discovery Into Health ®
According to the current listing, eligibility includes: Eligible United States small business concerns (SBCs). Confirm the full requirements in the official notice before applying.
Industrialization and Translation of Extracellular Vesicles for use in Regenerative Medicine (UT1/UT2) Clinical Trial Not Allowed is funded by National Institutes of Health (NIH). Verify program details on the funder's official page before applying.
Start from the official opportunity page linked in this listing — it carries the sponsor's submission instructions.
The All of Us X01 is a Resource Access Award, not a funding award. It conveys serum, plasma and genomic DNA from a 613,000-participant biobank, requires you to prove you already have the money, and gives you nine months of exclusivity before your own assay data goes public.
Read articleOLAW's new RFI asks whether institutions can report annual live vertebrate animal numbers with USDA pain and distress categories for species the Animal Welfare Act does not cover. Comments close December 21, 2026. The burden falls on the 90 percent of research animals nobody currently counts.
Read articleNOT-OD-26-089 expanded PAR-26-106 eligibility to for-profits, small businesses, and local governments effective January 25, 2027. It was rescinded on September 16, 2026. The revised announcement lists only universities and nonprofits — and the January 25 due date is still live.
Read article